We enable safe and efficient monitoring of tissues during cancer surgery without compromising workflows.
Rethinking surgery.
Marginum is developing groundbreaking tissue recognition technology, especially for oncological surgery.
Our technology assists in safe and efficient identification of cancerous tissue with minimal damage to healthy tissues.
Precise detection of tissue without additional invasive steps – based on internationally awarded research.
30.3.2026 | MARGINUM NEWS
Marginum launches a U.S. clinical study with the HIVEN® device at the University of Illinois Hospital & Clinics (UI Health) in Chicago.
19.3.2026 | Marginum News
ALMEDA, a Prague-based medical equipment distributor, has partnered with Marginum to distribute its HIVEN® device in the Czech Republic and Slovakia.
26.2.2026 | Neuro-Oncology Advances
A first-in-human study shows that HIVEN®-based aspirate tissue monitoring provides nearly 5 times more fluorescence information than visual guidance alone.
17.12.2025 | THE FINNISH MEDICAL FOUNDATION
CEO Samu Lehtonen has been nominated for the prestigious Pohjola Medical Innovation Award in recognition of the Marginum team’s scientific contributions.
3.11.2025 | BUSINESS FINLAND
Marginum has been selected for the prestigious Young Innovative Companies (YIC) program, a recognition reserved for Finland’s most promising startups.
20.10.2025 | MARGINUM NEWS
Marginum has completed the HIVEN® usability assessment at the University of Illinois College of Medicine Surgical Innovation and Training Laboratory.
Marginum is enabling better surgical performance and patient outcomes to answer the globally growing need for efficient oncological treatments.
Founded in 2020, Marginum is reforging the
technology of oncological surgery.
With the developed tissue detection technology for surgery, Marginum aims to make a real impact by helping millions of patients and surgical professionals around the globe.
Location: Kuopio, Finland
Email: info@marginum.com